Comparative Pharmacology
Head-to-head clinical analysis: COGNEX versus EXELON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COGNEX versus EXELON.
COGNEX vs EXELON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increases acetylcholine concentration at cholinergic synapses.
Exelon (rivastigmine) is a reversible, non-competitive acetylcholinesterase and butyrylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
Initial dose 10 mg orally 4 times daily (40 mg/day); may increase by 10 mg/day every 6 weeks up to 160 mg/day (40 mg 4 times daily).
Initial: 1.5 mg orally twice daily; after 2 weeks increase to 3 mg twice daily; then after 2 weeks increase to 4.5 mg twice daily; then after 2 weeks increase to 6 mg twice daily (maximum). For transdermal patch: initial 4.6 mg/24 hr applied once daily; after 4 weeks increase to 9.5 mg/24 hr; may increase to 13.3 mg/24 hr after additional 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 7-10 hours; clinical context: allows twice-daily dosing in most patients.
Terminal half-life: ~1.5 hours; clinical context: tid dosing recommended due to rapid elimination.
Primarily renal (approximately 40-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30%).
Renal (97%) with unchanged drug <1%; biliary/fecal as metabolites.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor